BELLUS Health Inc (BLU.CA)

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...

BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders

BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition

BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights

BELLUS Health Announces Meeting Updates

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

GSK to Buy Bellus for $2 Billion to Gain Cough Medicine

GSK Plc agreed to buy Canadian biotech Bellus Health Inc. for a total equity value of about $2 billion to bolster its pipeline of experimental medicines.

BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation

BELLUS Health Reports Year 2022 Financial Results and Business Highlights

BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference

BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting

BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting

BELLUS Health to Present at the H.C. Wainwright Global Investment Conference

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022

BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights

BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States

BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States

BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States

Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough

BELLUS Health to Participate in the William Blair Biotech Focus Conference

BELLUS Health to Participate in the Jefferies Healthcare Conference

BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights

BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference

BELLUS Health to Participate in Multiple Upcoming Investor Conferences

BELLUS Health Reports Year 2021 Financial Results and Business Highlights

BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States

BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States

BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States

BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937

BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

BELLUS Health to Present at the H.C. Wainwright Global Investment Conference

BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021

BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights

BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference